About 26S proteasome regulatory subunit 6B
26S proteasome regulatory subunit 6B (PSMC4) is a protein
from Homo sapiens identified by UniProt accession
P43686, 418 residues long.
MolForge cross-references it against 0 known binders and
67 disease associations.
Target properties
| Protein name | 26S proteasome regulatory subunit 6B |
| UniProt accession | P43686 |
| Gene | PSMC4 |
| Organism | Homo sapiens |
| Length | 418 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (67)
Diseases linked to this target (Open Targets).
- HIV infection · score 0.46
- lean body mass · score 0.33
- breast adenocarcinoma · score 0.30
- low grade glioma · score 0.29
- lung adenocarcinoma · score 0.29
- endometrial cancer · score 0.29
- esophageal cancer · score 0.28
- head and neck squamous cell carcinoma · score 0.28
- squamous cell lung carcinoma · score 0.28
- gastric adenocarcinoma · score 0.27
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P43686-F1 | alphafold | PREDICTED | 80.11 | — |
Amino-acid sequence (418 residues)
MEEIGILVEK AQDEIPALSV SRPQTGLSFL GPEPEDLEDL YSRYKKLQQE LEFLEVQEEY IKDEQKNLKK EFLHAQEEVK RIQSIPLVIG QFLEAVDQNT AIVGSTTGSN YYVRILSTID RELLKPNASV ALHKHSNALV DVLPPEADSS IMMLTSDQKP DVMYADIGGM DIQKQEVREA VELPLTHFEL YKQIGIDPPR GVLMYGPPGC GKTMLAKAVA HHTTAAFIRV VGSEFVQKYL GEGPRMVRDV FRLAKENAPA IIFIDEIDAI ATKRFDAQTG ADREVQRILL ELLNQMDGFD QNVNVKVIMA TNRADTLDPA LLRPGRLDRK IEFPLPDRRQ KRLIFSTITS KMNLSEEVDL EDYVARPDKI SGADINSICQ ESGMLAVREN RYIVLAKDFE KAYKTVIKKD EQEHEFYK
Explore 26S proteasome regulatory subunit 6B with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets